“Global Dementia Treatment Market to reach a market value of USD 29.2 Billion by 2031 growing at a CAGR of 7.4%”
The Global Dementia Treatment Market size is expected to reach $29.2 billion by 2031, rising at a market growth of 7.4% CAGR during the forecast period.
Alzheimer's disease is one of the most prevalent forms of dementia, responsible for a substantial proportion of dementia cases worldwide. As the disease progresses, individuals may experience confusion, mood swings, difficulty completing familiar tasks, and changes in personality and behavior. Hence, Alzheimer’s disease dementia captured 58% revenue share in the market in the year 2031. The symptoms of Alzheimer's disease typically begin gradually and worsen over time. In the later stages of the disease, individuals may require round-the-clock care as they lose the ability to communicate and care for themselves.
The increasing number of elderly people around the world is one of the most important factors that is driving the expansion of the market for dementia treatments. Individuals all over the world are living longer. As advancements in healthcare and living standards continue to extend life expectancy, the proportion of elderly individuals within populations is increasing. Consequently, the rising number of elderly individuals is leading to a higher incidence of dementia, necessitating effective treatment options and driving the growth of the market.
Additionally, the increasing prevalence of dementia and related conditions is a substantial global health concern that affects millions of individuals and their families. Dementia is currently affecting approximately 55 million individuals worldwide, according to the World Health Organisation (WHO). The increasing prevalence of dementia is fueling demand for effective treatments and interventions. People with dementia are increasingly in need of comprehensive healthcare strategies that encompass supportive care, effective medical treatments, and early diagnosis. Thus, the rising prevalence of dementia will aid in expanding the market.
However, Dementia care involves various medical, social, and supportive services, including medications, doctor visits, home care, and residential care. These expenses can accumulate rapidly, particularly as the disease advances and the necessity for care increases. Long-term care and support services can be particularly expensive, such as nursing home care or in-home care by trained professionals. This financial strain can be particularly severe in regions with limited access to affordable healthcare services, leading to delays in seeking care or inadequate treatment. Hence, the high cost of dementia treatments may hamper the market's growth.
Initially, the pandemic disrupted healthcare systems worldwide, diverting resources and attention away from non-COVID-19-related conditions, including dementia. This diversion resulted in delays in diagnosis and treatment for many dementia patients, leading to worsening symptoms and outcomes. On the other hand, the pandemic accelerated the adoption of telehealth and digital health technologies in dementia care, presenting new opportunities for industry. The integration of these technologies into dementia care not only mitigated the impact of the pandemic but also improved access to care for patients in rural or underserved areas. Therefore, the pandemic had an overall moderate impact on the market.
Based on type, the market is bifurcated into diagnosis and drugs. The drugs segment garnered 60% revenue share in the market in 2023. Patients with Alzheimer's disease or any other form of dementia frequently employ pharmacological treatments, such as cholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists, to alleviate symptoms and enhance cognitive function. The availability of these drugs, along with ongoing research and development activities aimed at developing new and more effective therapies, has driven the growth of the drugs segment in the market.
Based on dementia drugs route of administration, the market is segmented into oral, transdermal patch, and injectable. The oral segment procured the 32% share in the market in 2023. Oral medications are the most prevalent method of administration for dementia drugs, providing patients and carers with convenience and ease of use. Drugs such as cholinesterase inhibitors and NMDA receptor antagonists are typically administered orally, allowing for regular dosing and consistent blood levels, which are crucial for maintaining therapeutic effects in dementia management.
On the basis of dementia drugs distribution channel, the market is divided into hospital pharmacy, retail pharmacy, and online pharmacy. The retail pharmacy segment witnessed 16% revenue share in the market in 2023. Retail pharmacies, including chain pharmacies, independent pharmacies, and drug stores, are important sources of dementia medication for community patients. These pharmacies provide essential medications and counseling services for managing dementia symptoms and treatment regimens, providing convenience and accessibility for patients and carers.
By indication, the market is segmented into Alzheimer’s disease dementia, vascular dementia, Lewy body dementia, frontotemporal dementia (FTD), Parkinson disease dementia, and others. The Parkinson disease dementia segment procured 15% revenue share in the market in 2023. Parkinson's disease dementia is a common complication of Parkinson's disease, affecting a significant number of individuals with the condition.
Free Valuable Insights: Global Dementia Treatment Market size to reach USD 29.2 Billion by 2031
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment recorded 39% revenue share in the market in 2023. The growth of the market in this region can be attributed to a large elderly population, high healthcare spending, and advanced healthcare infrastructure in countries such as the United States and Canada. These factors contribute to the widespread availability of dementia treatments and services.
| Report Attribute | Details |
|---|---|
| Market size value in 2023 | USD 16.7 Billion |
| Market size forecast in 2031 | USD 29.2 Billion |
| Base Year | 2023 |
| Historical Period | 2020 to 2022 |
| Forecast Period | 2024 to 2031 |
| Revenue Growth Rate | CAGR of 7.4% from 2024 to 2031 |
| Number of Pages | 409 |
| Number of Tables | 680 |
| Report coverage | Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Porter’s 5 Forces Analysis, Company Profiling, Companies Strategic Developments, SWOT Analysis, Winning Imperatives |
| Segments covered | Type, Dementia Drugs Route of Administration, Dementia Drugs Distribution Channel, Indication, Region |
| Country scope |
|
| Companies Included | Eisai Co., Ltd., Eli Lilly And Company, F. Hoffmann-La Roche Ltd., Biogen, Inc., AbbVie, Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, GlaxoSmithKline PLC (GSK), Cipla Limited. |
By Type
By Dementia Drugs Route of Administration
By Dementia Drugs Distribution Channel
By Indication
By Geography
This Market size is expected to reach $29.2 billion by 2031.
Rising Proportion of The Aging Population are driving the Market in coming years, however,Lack of Early Diagnosis restraints the growth of the Market.
Eisai Co., Ltd., Eli Lilly And Company, F. Hoffmann-La Roche Ltd., Biogen, Inc., AbbVie, Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, GlaxoSmithKline PLC (GSK), Cipla Limited.
The expected CAGR of this Market is 7.4% from 2023 to 2031.
The Diagnosis segment is leading the Market by Type in 2023; thereby, achieving a market value of $12.8 billion by 2031.
The North America region dominated the Market by Region in 2023; thereby, achieving a market value of $11 billion by 2031.
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 